Foster Trenton, Dy Benzon, Rocco Raffaele, Mckenzie Travis, Thompson Geoffrey, Wermers Robert, Lyden Melanie
Department of Surgery, 6915Mayo Clinic, Rochester, MN, USA.
Department of Medicine, 6915Mayo Clinic, Rochester, MN, USA.
Am Surg. 2022 Feb;88(2):254-259. doi: 10.1177/0003134821991991. Epub 2021 Jan 31.
In Jan 2018, we began routinely obtaining neck ultrasound (US) with 123I/99Tc-sestamibi (MIBI) for parathyroid gland localization and to identify thyroid pathology in the setting of primary hyperparathyroidism (1HPT). The aim of this study is to assess if routine neck US is a useful adjunct to 123I/99Tc-MIBI in 1HPT.
Patients undergoing surgery for 1HPT with both 123I/99Tc-MIBI and US at our institution after implementation of routine US were reviewed. Biopsy and surgical management of thyroid pathology was evaluated. 123I/99Tc-MIBI and US results were compared to intraoperative findings to determine sensitivity and positive predictive value (PPV) for parathyroid localization.
From January 2018 to September 2019, there were 423 patients (mean, 61 years) that met inclusion criteria (80% women). Thyroid nodules were found on US in 57%, mean size 1.3 + 0.8 cm. Fine needle aspiration (FNA) was performed in 87 patients with nodules (36%). 35 patients (8.5%) required total or partial thyroidectomy for diagnoses/treatment. Papillary thyroid cancer (PTC) was found in 3.5% of the cohort with micro-PTC 53% and PTC 1-2 cm 40%. A successful parathyroid operation for 1HPT was achieved in 98.6% of patients. Positive predictive value for localization of abnormal parathyroid glands was 97% when US and 123I/99Tc-MIBI had concordant findings.
Routine use of US in 1HPT commonly identifies nodules that are benign or low-risk PTC. Ultrasound is less sensitive for parathyroid localization but when used with 123I/99Tc-MIBI, concordant imaging has a high PPV.
2018年1月,我们开始常规进行颈部超声(US)检查,并结合123I/99Tc - 甲氧基异丁基异腈(MIBI)用于甲状旁腺定位以及在原发性甲状旁腺功能亢进症(1HPT)患者中识别甲状腺病变。本研究的目的是评估常规颈部超声在1HPT患者中是否是123I/99Tc - MIBI的有用辅助检查。
回顾了在我院实施常规超声检查后接受1HPT手术且同时进行了123I/99Tc - MIBI和超声检查的患者。对甲状腺病变的活检和手术处理情况进行了评估。将123I/99Tc - MIBI和超声检查结果与术中发现进行比较,以确定甲状旁腺定位的敏感性和阳性预测值(PPV)。
2018年1月至2019年9月,有423例患者(平均年龄61岁)符合纳入标准(80%为女性)。超声检查发现57%的患者有甲状腺结节,平均大小为1.3 + 0.8厘米。87例有结节的患者(36%)进行了细针穿刺活检(FNA)。35例患者(8.5%)因诊断/治疗需要进行了全甲状腺或部分甲状腺切除术。在该队列中,3.5%的患者被发现患有乳头状甲状腺癌(PTC),其中微小PTC占53%,直径1 - 2厘米的PTC占40%。98.6%的患者成功进行了1HPT甲状旁腺手术。当超声和123I/99Tc - MIBI检查结果一致时,异常甲状旁腺定位的阳性预测值为97%。
在1HPT中常规使用超声通常能发现良性或低风险PTC的结节。超声对甲状旁腺定位的敏感性较低,但与123I/99Tc - MIBI联合使用时,检查结果一致时具有较高的PPV。